



Figure S1. Funnel plots of a meta-analysis comparing the outcomes of interests between participants who received an additional heterologous (viral vector) and homologous (mRNA) COVID-19 vaccination. (A) anti-SARS-CoV-2 spike protein (anti-S) IgG seropositivity rates; (B) SARS-CoV-2-specific T-cell immune response rates; (C) incidence of pain at the injection site; (D) incidence of headache; (E) incidence of fatigue; (F) incidence of myalgia; and (G) incidence of arthralgia.